Combination and method including a visual marker for determining compliance with a medication regimen

• US 7,062,312 B2
• Filed: 01/17/2001
• Issued: 06/13/2006
• Est. Priority Date: 01/17/2001
• Status: Expired due to Fees

• Current Assignee: Union Springs Pharmaceuticals, LLC
• Original Assignee: Pediamed Pharmaceuticals, Inc.
• Inventors: Gonzales, Gilbert R., Griggs, Roger D.
• Primary Examiner(s): Robert, Eduardo C.
• Assistant Examiner(s): RAMANA, ANURADHA
• Application Number:
  US09/765,151
• Publication Number:
  US 20020095072A1
• Time in Patent Office: 1,973 Days
• Field of Search: 600/431, 600/407, 600/425, 600476-478, 600/473, 600/160, 424/9.7, 424/10.3, 424/10.1, 424439-442, 348/77, 514/849, 514/850, 514/853, 514/855, 514/900, 514/901, 514/902, 436/56, 436/169
• US Class Current: 600/476
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Abstract

A method and combination including a visual marker for monitoring a patient to determine compliance with a medication regimen. An orally administrable medication composition is provided in combination with a visual marker. When the combination is orally ingested, the marker causes a coloration or discoloration of the oral and/or pharyngeal cavity of a subject. By visually observing the oral and/or pharyngeal cavity of the subject, one can determine whether medication has been ingested based upon the presence or absence of the coloration/discoloration.

Claims

1. A method of monitoring the compliance of a patient in following a medication regimen, said method comprising the steps of:

providing in combination an orally administrable composition, which is part of a medication regimen, and multiple markers present in said combination, one of said markers causing a contact coloration of at least a portion of a mucous membrane or buccal membrane of the oral and/or pharyngeal cavity of a patient following oral ingestion of said combination by said patient for a longer time than another of said markers, the half-life of at least one marker being comparable to the half-life of said composition;

visually observing the oral and/or pharyngeal cavity of said patient;

determining the presence or absence of said contact coloration for determining whether said patient has ingested said combination in compliance with the medication regimen; and

determining the presence or absence of contact coloration caused by the multiple markers to determine a time frame in which the combination was ingested.

2. The method of claim 1 wherein said composition is a medication composition.

3. The method of claim 1 wherein said composition is a placebo composition.

4. The method of claim 1 wherein visually observing the oral and/or pharyngeal cavity of said patient to determine the presence or absence of contact coloration further comprises the step of directing natural light into the oral and/or pharyngeal cavity of said patient prior to observing the oral and/or pharyngeal cavity of said patient in order to directly observe said contact coloration.

5. The method of claim 1 wherein visually observing the oral and/or pharyngeal cavity of said patient to determine the presence or absence of contact coloration further comprises the step of directing an optimal exciting light into the oral and/or pharyngeal cavity of said patient prior to observing the oral and/or pharyngeal cavity of said patient in order to observe said contact coloration through fluorescence.

6. The method of claim 5 wherein said optimal exciting light is a violet-blue to blue light having a wavelength in a range of from about 430 nm to about 490 nm.

7. The method of claim 1 wherein visually observing said oral and/or pharyngeal cavity comprises visually observing a mucous membrane in said oral and/or pharyngeal cavity.

8. The method of claim 1 wherein said marker is carmine red dye.

9. The method of claim 1 wherein said marker is selected from the group consisting of indigo carmine, methylene blue, tartrazine, laccaic acid, beta-carotene, FD&

C Blue No. 1, FD&

C Blue No. 2, FD&

C Green No. 3, FD&

C Red No. 3, FD&

C Red No. 40, FD&

C Yellow No. 6, and riboflavin.

10. The method of claim 1 wherein one of said multiple markers causes a different contact coloration in the portion of the oral and/or pharyngeal cavity than another of said markers.

11. The method of claim 1 further comprising providing multiple markers in said combination wherein one of said multiple markers causes a different contact coloration in the portion of the oral and/or pharyngeal cavity than another of said markers.

12. The method of claim 1 further comprising providing multiple markers in said combination, one of said markers causing a contact coloration of a portion of the oral and/or pharyngeal cavity detectable with natural light and another of said markers causing contact coloration detectable with a light which causes fluorescence.

13. The method of claim 1 further comprising providing multiple markers in said combination, the markers being detectable with a light which causes fluorescence, one of said markers causing a different fluorescent contact coloration of a portion of the oral and/or pharyngeal cavity than the fluorescent contact coloration caused by the other marker.

14. The method of claim 1, wherein said combination is in a form and sufficient amount to cause a contact coloration directly on at least a portion of a mucous membrane or buccal membrane of the oral and/or pharyngeal cavity.

15. In combination:

an orally administrable composition; and

multiple markers, wherein one of said multiple markers causes a contact coloration of at least a portion of a mucous membrane or buccal membrane of the oral and/or pharyngeal cavity of a patient for a longer time than another of the markers following ingestion of said combination by said patient, the half-life of said marker being comparable to the half-life of said composition;

said contact coloration of the oral and/or pharyngeal cavity being visually observable for determining whether said patient has ingested said combination in compliance with a medication regimen and for determining a time frame in which the combination was ingested.

16. The combination of claim 15 wherein said at least one marker is applied to the outer surface of said composition.

17. The combination of claim 15 wherein said at least one marker is interspersed throughout said composition.

18. The combination of claim 15 wherein the form of said composition is selected from the group consisting of a chewable tablet, a pill, a capsule, and a liquid.

19. The combination of claim 15 wherein said marker is operable to cause contact coloration of a mucous membrane of said oral and/or pharyngeal cavity.

20. The combination of claim 15 wherein said at least one marker is carmine red dye.

21. The combination of claim 15 wherein said at least one marker is selected from the group consisting of indigo carmine, methylene blue, tartrazine, laccaic acid, beta-carotene, FD&

C Blue No. 1, FD&

C Blue No. 2, FD&

C Green No. 3, FD&

C Red No. 3, FD&

C Red No. 40, FD&

C Yellow No. 6, and riboflavin.

22. The combination of claim 15 wherein one of said multiple markers causes a different contact coloration in the portion of the oral and/or pharyngeal cavity than another of said markers.

23. The combination of claim 15 wherein one of said multiple markers causes a contact coloration of a portion of the oral and/or pharyngeal cavity detectable with natural light and another of said markers causes contact coloration detectable with a light which causes fluorescence.

24. The combination of claim 15 wherein the multiple markers are detectable with a light which causes fluorescence, one of said markers causing a different fluorescent contact coloration of a portion of the oral and/or pharyngeal cavity than the fluorescent contact coloration caused by the other marker.